Solasia Pharma invests in Isofol to boost SP-05 development

Solasia Pharma Kk has announced that its board of directors has resolved to invest in Isofol Medical AB (Nasdaq Stockholm), the rights holder and development partner for its SP-05 asset, a treatment for colorectal cancer. The investment will be in the form of Solasia acquiring newly issued shares in Isofol. The investment, totaling SEK 4,999,996.80, will grant Solasia a 2.2% stake in Isofol. As part of the agreement, Solasia will also receive warrants to acquire an additional 4,166,664 shares. Solasia plans to use funds allocated for SP-05 development to cover this investment. This decision aims to strengthen collaboration with Isofol, particularly for ongoing SP-05 clinical trials and potential commercialization in regions outside Japan. Solasia does not expect this investment to impact its 2025 financial forecast.